When you have a potentially life-threatening allergy, you must be vigilant. Accidental exposure to an allergen might be fatal. If you are a health care professional and have a latex allergy, the recent updated glove use guidelines issued by the Food and Drug Administration (FDA) has made that vigilance even more challenging. By relaxing the guidelines, the FDA may have created an environment where there are more latex proteins in a healthcare setting.
In March, the U.S. Food and Drug Administration (FDA) updated its glove use guidelines for healthcare professionals during the COVID-19 pandemic. These guidelines, however, loosen latex allergy standards and may potentially put people with latex allergy at risk.
The guidelines include no precautions or education for latex allergy patients and there is no latex warning required on glove labels. The action also suggests that healthcare professionals can extend use of medical gloves between patients, a poor use of glove practice. As a result of these guidelines, latex proteins may now be more present in healthcare settings.
Because of the coronavirus, the Food and Drug Administration has recently issued interim food labeling guidelines, in response to possible supply chain issues and shortages. These guidelines created confusion as to “what’s in, what’s out and what’s new” in food products. As a result, there have been responses and reactions from throughout the food allergy community. From petitions to letters, from comments to FDA to calls for clarity regarding these guidelines, our community has been vocal in response to these changes. And the FDA heard us. The FDA has developed a FAQ page and provided additional guidance to help clarify its new guidelines.
If you suffer from a food allergy, a food’s product label is essential reading. It can help determine what foods are safe to eat and which are not. Because of the coronavirus, the FDA recently has issued interim food labeling guidelines, in response to possible supply chain issues and shortages. These changes produced confusion and frustration among numerous allergy suffers. The Allergy Advocacy Association, working with other members of the food allergy community, lobbied the FDA about the possible impact these label guideline changes could have. To provide a
better understanding of these interim requirements the FDA has developed a FAQ page.
A game changer is defined as “an event, idea, or procedure that effects a significant shift in the current manner of doing or thinking about something.” The possibility of a pill that could prevent anaphylaxis has that potential. For those that suffer from life threatening allergies, the ability to proactively deal with anaphylaxis would not only be welcomed relief, it could provide comfort and reassurance to their loved ones, as well as saving countless lives. And that truly would be a game changer.
For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause. Anaphylaxis is a severe, potentially life-threatening systemic allergic reaction that can occur within seconds or minutes of exposure to an allergen. It occurs in about one in 50 Americans, though many believe the rate is higher (closer to one in 20), according to the Asthma and Allergy Foundation of America. If a person’s blood pressure drops so low during anaphylaxis or their airway closes enough that they can’t get enough oxygen to their organs, they enter anaphylactic shock.
The race for a vaccine to the coronavirus, can be felt in many places. From hospitals to research facilities, from schools to businesses, big and small, to even the halls of Capitol Hill. In pursuit of a vaccine, the issue of drug pricing, appears to of slowed if not stalled in Congress. The race for a vaccine, with lessened regulation and increased federal monies for drug research and innovation, have provided the pharmaceutical industry increased leverage in the drug pricing battle. While we all hope for a vaccine to the coronavirus soon, lawmakers must be reminded of the drug makers past behavior with drug pricing and the need for affordable lifesaving medicine.
With people hoping for a coronavirus vaccine, Congress has less leverage to rein in the industry.
By Riley Griffin and Emma Court June 18, 2020
When a headhunter for the drug industry approached Michelle McMurry-Heath in January about taking the helm of a powerful trade group, she brushed off the offer. She wasn’t interested in making “bad-smelling” positions palatable to Washington. “If you’re looking for a typical lobbyist,” she recalls saying, “I’m not that person.”
COVID-19 has certainly brought to everyone’s attention that people with asthma are at a greater risk of severe illness and hospitalization if they contract the virus. The Asthma and Allergy Foundation of America (AAFA) and the MedicAlert Foundation have joined forces to develop an online asthma or anaphylaxis treatment plan that will be part of a MedicAlert member’s health profile. In an emergency, MedicAlert will relay the action plan and other critical medical information to first responders to ensure fast and accurate treatment. If you have asthma or a life-threatening allergy, now is the time to get yourself a MedicAlert ID!
Washington, D.C., May 05, 2020 (GLOBE NEWSWIRE) -- Over 65 million people in the United States live with asthma or allergies to food, drugs or other allergens. Tragically, 3,600 people die each year from asthma – deaths that are often preventable. COVID-19 poses additional danger to these populations. Two leading non-profits have joined forces to raise awareness and provide resources for living with these potentially life-threatening conditions: asthma and anaphylaxis.